Literature DB >> 2996283

Immunocytochemical studies of serum proteins and immunoglobulins in human sural nerve biopsies.

U G Liebert, R J Seitz, T Weber, W Wechsler.   

Abstract

Post-embedding immunocytochemical studies on immunoglobulins (Ig) and other serum proteins were carried out on 38 human sural nerve biopsies using the PAP method. In addition to toxic, hereditary, metabolic, dysproteinemic, and vasculitic-neuritic neuropathies, morphologically normal sural nerves were included as controls. The intensity of the immunocytochemical reactions was strong for proteins, such as IgG, the light chains of Igs, and albumin, but weak or absent for others like complement component C3, IgA, ceruloplasmin, and alpha-1-antitrypsin (AAT) in normal nerve biopsies and in all pathologic groups. IgG, the light chains of immunoglobulins, and albumin could readily be detected in perineurium, endoneurial interstitium, and blood vessel walls. IgM, C3, and beta-lipoprotein (BLP) were largely confined to the walls of blood vessels and perineurium, thus indicating that they do not penetrate the blood nerve barrier. Only in a few cases, in vasculitic-neuritic and dysproteinemic neuropathies, staining of the endoneurial interstitium for IgM and C3 was observed. Increased staining for the corresponding heavy or light chains was not detected in the endoneurium in any of the neuropathies associated with gammopathy. The results stress that PAP immunocytochemistry is suitable for studying the blood-nerve barrier (BNB) and provides new aspects to the concept of the BNB with respect to the steady state of serum proteins between endoneurial and vascular spaces. It is suggested that, in addition to serum concentration and molecular weight of serum proteins, the permeability of the BNB is influenced by other yet undefined factors.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2996283     DOI: 10.1007/bf00688954

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  25 in total

1.  Clinical applications of the enzyme labeled antibody method. Immunoperoxidase methods in diagnostic histopathology.

Authors:  F T Bosman; A C Nieuwenhuijzen Kruseman
Journal:  J Histochem Cytochem       Date:  1979-08       Impact factor: 2.479

2.  The use of proteolytic enzymes to improve immunoglobulin staining by the PAP technique.

Authors:  B L Mepham; W Frater; B S Mitchell
Journal:  Histochem J       Date:  1979-05

3.  Studies on vascular permeability in peripheral nerves. IV. Distribution of intravenously injected protein tracers in the peripheral nervous system of various species.

Authors:  Y Olsson
Journal:  Acta Neuropathol       Date:  1971       Impact factor: 17.088

4.  Peripheral nerve microenvironment: collection of endoneurially enriched fluid.

Authors:  P A Low; J K Yao; J F Poduslo; D E Donald; P J Dyck
Journal:  Exp Neurol       Date:  1982-07       Impact factor: 5.330

5.  A study of the perineurium in peripheral nerve pathology.

Authors:  D J de la Motte; S M Hall; G Allt
Journal:  Acta Neuropathol       Date:  1975-12-19       Impact factor: 17.088

6.  The mouse blood-brain barrier and blood-nerve barrier for IgG: a tracer study by use of the avidin-biotin system.

Authors:  R J Seitz; K Heininger; G Schwendemann; K V Toyka; W Wechsler
Journal:  Acta Neuropathol       Date:  1985       Impact factor: 17.088

7.  Morphological correlates of permeability in the frog perineurium: vesicles and "transcellular channels".

Authors:  N L Shinowara; M E Michel; S I Rapoport
Journal:  Cell Tissue Res       Date:  1982       Impact factor: 5.249

8.  Plasma proteins in human peripheral nerve.

Authors:  J M Van Lis; F G Jennekens
Journal:  J Neurol Sci       Date:  1977-12       Impact factor: 3.181

9.  Neuropathy accompanying IgM lambda monoclonal gammopathy.

Authors:  K Stefansson; L Marton; J P Antel; R L Wollmann; R P Roos; G Chejfec; B G Arnason
Journal:  Acta Neuropathol       Date:  1983       Impact factor: 17.088

10.  Demyelinating polyneuropathy associated with monoclonal IgM-paraproteinaemia. Histological, ultrastructural and immunocytochemical studies.

Authors:  C Meier; M Vandevelde; A Steck; A Zurbriggen
Journal:  J Neurol Sci       Date:  1984-03       Impact factor: 3.181

View more
  7 in total

1.  The clinical spectrum of peripheral neuropathies associated with benign monoclonal IgM, IgG and IgA paraproteinaemia. Comparative clinical, immunological and nerve biopsy findings.

Authors:  K B Yeung; P K Thomas; R H King; H Waddy; R G Will; R A Hughes; N A Gregson; S Leibowitz
Journal:  J Neurol       Date:  1991-10       Impact factor: 4.849

2.  Polyneuropathy associated with IgM monoclonal gammopathy. Immunological and pathological study in 31 patients.

Authors:  A Vital; C Vital; J Julien; A Baquey; A J Steck
Journal:  Acta Neuropathol       Date:  1989       Impact factor: 17.088

3.  Significance of lymphocytes and blood vessel changes for edema formation in polyradiculoneuritis.

Authors:  R J Seitz; E Neuen-Jacob; W Wechsler
Journal:  Acta Neuropathol       Date:  1988       Impact factor: 17.088

4.  The mouse blood-brain barrier and blood-nerve barrier for IgG: a tracer study by use of the avidin-biotin system.

Authors:  R J Seitz; K Heininger; G Schwendemann; K V Toyka; W Wechsler
Journal:  Acta Neuropathol       Date:  1985       Impact factor: 17.088

5.  Vascular permeability changes in tumours of the peripheral nervous system.

Authors:  R Schober; K T Vogeley; H Urich; E Hölzle; W Wechsler
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

6.  The leakage of serum proteins across the blood-nerve barrier in hereditary and inflammatory neuropathies. An immunohistochemical and morphometric study.

Authors:  E Neuen; R J Seitz; M Langenbach; W Wechsler
Journal:  Acta Neuropathol       Date:  1987       Impact factor: 17.088

7.  Induction of autoimmune reactions to myelin basic protein in measles virus encephalitis in Lewis rats.

Authors:  U G Liebert; C Linington; V ter Meulen
Journal:  J Neuroimmunol       Date:  1988-01       Impact factor: 3.478

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.